Drug Type Small molecule drug |
Synonyms Erlosamide, Harkoseride, Lacosamide (JAN/USAN/INN) + [16] |
Target |
Action blockers |
Mechanism Sodium channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (29 Aug 2008), |
RegulationPriority Review (China) |
Molecular FormulaC13H18N2O3 |
InChIKeyVPPJLAIAVCUEMN-GFCCVEGCSA-N |
CAS Registry175481-36-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07299 | Lacosamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsy | European Union | 18 Sep 2017 | |
Epilepsy | Iceland | 18 Sep 2017 | |
Epilepsy | Liechtenstein | 18 Sep 2017 | |
Epilepsy | Norway | 18 Sep 2017 | |
Epilepsy, Tonic-Clonic | Japan | 04 Jul 2016 | |
Epilepsy, Idiopathic Generalized | Australia | 20 Jul 2009 | |
Seizures | Australia | 20 Jul 2009 | |
Epilepsies, Partial | European Union | 29 Aug 2008 | |
Epilepsies, Partial | Iceland | 29 Aug 2008 | |
Epilepsies, Partial | Liechtenstein | 29 Aug 2008 | |
Epilepsies, Partial | Norway | 29 Aug 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy, Complex Partial | Phase 3 | United States | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Australia | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Austria | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Canada | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Denmark | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | France | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Germany | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Ireland | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Italy | 01 Aug 2007 | |
Epilepsy, Complex Partial | Phase 3 | Poland | 01 Aug 2007 |
Not Applicable | Status Epilepticus First line | Second line | Third line | - | mfqjnbeuvq(wcmpxqmcuz) = qpawgkzain izbqtquqjr (gjydfwfjmw ) View more | Positive | 07 Apr 2025 | ||
mfqjnbeuvq(wcmpxqmcuz) = zhlqwgjkme izbqtquqjr (gjydfwfjmw ) | |||||||
Phase 3 | 239 | yfvvuceenj(rtuslktskq) = olghlsgzan vmxxoutmea (wlljdfskae ) View more | Positive | 26 Oct 2024 | |||
Not Applicable | - | ybbaeuivud(juzkpqiobl) = hiqclojzzs mmirjvfnnp (dfjyuigxys ) View more | - | 09 Apr 2024 | |||
Lacosamide polytherapy | ybbaeuivud(juzkpqiobl) = zyrftejihd mmirjvfnnp (dfjyuigxys ) View more | ||||||
Phase 3 | 239 | koyfgnpcio = vmdgxugxhy fllzrasiux (hlvxcurkog, eavoqlemqn - gingnfryvo) View more | - | 14 Dec 2023 | |||
Phase 2 | - | Lacosamide up to 12 mg/kg/day or 600 mg/day | uvdlyyknyu(carsohioav) = akhynnhytv wrjzctuiyv (czvfuxivjo ) | Positive | 01 Nov 2023 | ||
Not Applicable | 62 | ijwhzfthyi(xmjsfgbbjs) = Adverse events (AEs) were reported in 53%, none of which were attributed to lacosamide xebkwhrimn (vgpsgihffd ) View more | - | 01 Oct 2023 | |||
Not Applicable | Second line | 67 | ecdlccgiym(oknogkeoor) = 18 (26.9%) patient experienced bradycardia wlygzlegnn (tvyijwmsre ) View more | Positive | 04 Sep 2023 | ||
Not Applicable | - | petczlmmkt(ksnnsjxupt) = No side effects kqkilfasjl (fzbowbzjan ) View more | - | 04 Sep 2023 | |||
Phase 3 | 371 | wgfxcqutrw = hueskpfnqj sswmefufcb (llgopcevqh, fmwfqgbvux - dcvvrzjifo) View more | - | 24 Jul 2023 | |||
Not Applicable | 676 | ugwenzkatc(fxhubgqtfu) = gamyktmoux tvqxrszuue (pzmikgrtbq, 1 - 480) | Positive | 25 Apr 2023 |